- Home
- ECVT vs ANAB Comparison
ECVT vs ANAB Comparison
Compare ECVT & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECVT
- ANAB
- Stock Information
- Founded
- ECVT 1935
- ANAB 2005
- Country
- ECVT United States
- ANAB United States
- Employees
- ECVT N/A
- ANAB N/A
- Industry
- ECVT Major Chemicals
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- ECVT Industrials
- ANAB Health Care
- Exchange
- ECVT Nasdaq
- ANAB Nasdaq
- Market Cap
- ECVT 791.1M
- ANAB 759.5M
- IPO Year
- ECVT 2017
- ANAB 2017
- Fundamental
- Price
- ECVT $7.05
- ANAB $19.58
- Analyst Decision
- ECVT Strong Buy
- ANAB Buy
- Analyst Count
- ECVT 4
- ANAB 10
- Target Price
- ECVT $10.00
- ANAB $37.75
- AVG Volume (30 Days)
- ECVT 1.1M
- ANAB 605.6K
- Earning Date
- ECVT 05-01-2025
- ANAB 05-05-2025
- Dividend Yield
- ECVT N/A
- ANAB N/A
- EPS Growth
- ECVT N/A
- ANAB N/A
- EPS
- ECVT N/A
- ANAB N/A
- Revenue
- ECVT $706,153,000.00
- ANAB $111,872,000.00
- Revenue This Year
- ECVT $12.44
- ANAB N/A
- Revenue Next Year
- ECVT $5.15
- ANAB $44.69
- P/E Ratio
- ECVT N/A
- ANAB N/A
- Revenue Growth
- ECVT 2.23
- ANAB 387.20
- 52 Week Low
- ECVT $5.24
- ANAB $12.21
- 52 Week High
- ECVT $10.16
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- ECVT 70.32
- ANAB 48.91
- Support Level
- ECVT $5.68
- ANAB $19.57
- Resistance Level
- ECVT $5.95
- ANAB $21.52
- Average True Range (ATR)
- ECVT 0.28
- ANAB 1.19
- MACD
- ECVT 0.17
- ANAB -0.22
- Stochastic Oscillator
- ECVT 89.58
- ANAB 26.72
About ECVT Ecovyst Inc.
Ecovyst Inc is an integrated and provider of materials, specialty catalysts and services. Its products contribute to lower emissions and cleaner air, higher fuel efficiency and cleaner fuels, and key enablers to advance transition to clean energy. The company has two reporting segments: (1) Ecoservices and (2) Advanced Materials & Catalysts. Ecoservices provides sulfuric acid recycling to the North American refining industry for the production of alkylate and provides on-purpose virgin sulfuric acid for water treatment, mining, and industrial applications. Maximum revenue is generated from Ecoservices segment.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).